Saturday, September 25, 2021
Redactor's Choice
You are here: Home / Tag: pfizer

Tag: pfizer

One Year Later: Pfizer Update on Progress of Humanitarian Assistance Program


In January 2017, our multi dose vial (MDV) of PCV became available in the world's poorest countries through our partnership with Gavi, the Vaccine Alliance. It has also been used to vaccinate children in refugee settings. This four-in-one vial addresses the unique conditions and challenges experienced in developing world settings and can help health workers in humanitarian emergencies. The MDV, which has been qualified by the World Health Organization, has cold storage and transportation efficiencies, helping to enable vaccination of more child... Read More »

Pfizer Launches Zavicefta™ (ceftazidime-avibactam) In The U.K. And Germany, A New Antibiotic To Treat Complicated Infections Caused By Gram-Negative Bacteria


In June 2016, the European Medicines Agency (EMA) approved the marketing authorization for Zavicefta based on an extensive clinical trial program. Zavicefta is indicated for the treatment of adults with complicated intra-abdominal infection (cIAI), complicated urinary tract infection (cUTI) and Hospital-Acquired Pneumonia (HAP), including Ventilator Associated Pneumonia (VAP). Zavicefta is also indicated for the treatment of infections due to aerobic Gram-negative organisms in adult patients with limited treatment options. Zavicefta addresses P... Read More »

Pfizer Prices €4,000,000,000 Debt Offering


Interest on the floating rate notes will be three month EURIBOR plus 0.20%, reset quarterly. Pfizer intends to use the net offering proceeds for general corporate purposes, including to repay a portion of its outstanding commercial paper. Pfizer intends to apply to list the notes on the New York Stock Exchange. The closing of the offering is expected to occur on March 6, 2017, subject to satisfaction of customary closing conditions. Barclays Bank PLC, BNP Paribas, Goldman, Sachs & Co. and J.P. Morgan Securities plc are acting as joint... Read More »

Pfizer Receives Positive CHMP Opinion in Europe for XELJANZ® (tofacitinib citrate) for the Treatment of Moderate to Severe Active Rheumatoid Arthritis


“More than 2.9 million people are currently living with moderate to severe rheumatoid arthritis in Europe. Even with multiple therapeutic options, many of these people may not adequately respond to currently available treatments, including methotrexate,” said Michael Corbo, Chief Development Officer, Inflammation & Immunology, Global Product Development. “The positive CHMP opinion for tofacitinib is an important milestone as we work to bring this new oral treatment option to people in the European Union living with moderate to severe active... Read More »

Pfizer Announces Positive Top-Line Results from the Comparative REFLECTIONS B538-02 Study for PF-06410293, a Potential Biosimilar to Humira®1 (adalimumab)


“Today’s announcement builds on Pfizer’s robust biosimilar pipeline which has now delivered positive top-line data results for three of our proposed biosimilars,” said Sumant Ramachandra, MD, PhD, MBA, Head of Research and Development, Pfizer Essential Health. “As the leading global biosimilars company, we continue to advance our commitment to expand access to high-quality treatment options for patients living with chronic, debilitating conditions, such as those in inflammation. Inflammation remains one of the core research areas for Pfizer, sp... Read More »

Pfizer Completes Acquisition of Small Molecule Anti-Infective Business From AstraZeneca


“The addition of AstraZeneca’s complementary small molecule anti-infectives portfolio enhances our global expertise and offerings in an increasingly important area of therapeutics that addresses the public health needs of patients and healthcare professionals. Additionally this acquisition is an example of how we are focusing our investments to drive sustainable revenue growth potential for our Essential Health business,” said John Young, group president, Pfizer Essential Health. About the acquired assets Product Indica... Read More »

Anthony J. Maddaluna, Executive Vice President and President of Pfizer Global Supply to Retire


“I have had the privilege of working with Tony during much of his career, and he has been a valuable partner to me,” said Ian Read, chairman and chief executive officer, Pfizer. “Tony has continually demonstrated a steadfast commitment to Pfizer and our mission. His focus on quality, compliance and customer service has established Pfizer Global Supply as an industry leading supply organization that is highly respected by internal and external stakeholders. I know I join all Pfizer colleagues in thanking Tony for his tireless efforts and wishing... Read More »

Spark Therapeutics and Pfizer Announce Updated Data from Hemophilia B Phase 1/2 Trial Suggesting Sustained Therapeutic Levels of Factor IX Activity


The results are from the first seven participants who received a single administration of investigational SPK-9001 at a dose of 5 x 1011 vector genomes (vg)/kg body weight. Four of the seven participants had reached greater than 12 weeks post-vector administration at the time of abstract submission; those four participants experienced consistent and sustained factor IX activity levels, with a mean greater than 30% of normal, with no sustained elevation in liver enzyme levels. Spark Therapeutics and Pfizer report that one participant, who had... Read More »

Pfizer Announces The U.S. Availability Of Biosimilar INFLECTRA® (infliximab-dyyb)


INFLECTRA will be the first biosimilar monoclonal antibody (mAb) and only the second biosimilar to be available in the U.S. It is approved for the treatment of: adult patients and pediatric patients (ages six years and older) with moderate to severely active Crohn’s disease who have had an inadequate response to conventional therapy; adult patients with moderate to severely active ulcerative colitis who have had an inadequate response to conventional therapy; and moderate to severely active rheumatoid arthritis in combination with metho... Read More »

First Positive Phase 3 Results In Adjuvant Setting For Renal Cell Carcinoma Show SUTENT® (sunitinib) Extended Disease Free Survival After Surgical Removal

Pfizer logo 2013

Pfizer Inc. (NYSE:PFE) today announced results from the Phase 3 S-TRAC clinical trial (Sunitinib Trial as Adjuvant Treatment of Renal Cancer) investigating SUTENT® (sunitinib) as adjuvant therapy. The trial showed SUTENT extended disease-free survival (DFS) by more than one year versus placebo in patients who were at high risk for recurrence after surgical resection of renal cell carcinoma (RCC) (HR 0.761; P=0.030 [95% CI: 0.594-0.975]). These results will be presented today during a Presidential Symposium (Abstract #LBA11_PR) at the ESMO 2016 ... Read More »

Scroll To Top